How well does osimertinib—with or without chemotherapy—work to control EGFR-positive #LungCancer in patients not participating in a clinical trial? The PrE1702 #RealWorldData research study aims to find out. Learn more: https://t.co/OIWah87i9t #LCSM#RWD#RWE
.@teekayowo of @UMGCCC is leading PrE0510, a phase 2 #ClinicalTrial treating patients with extensive-stage small cell lung cancer (#SCLC) who have not yet had systemic therapy. Learn more: https://t.co/UUMDN1Nk2a #LCSM#LungCancer#SCLC
The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: https://t.co/OIWah87i9t #LCSM#RWD#RWE
How well does osimertinib—with or without chemotherapy—work to control EGFR-positive #LungCancer in patients not participating in a clinical trial? The PrE1702 #RealWorldData research study aims to find out. Learn more: https://t.co/OIWah87i9t #LCSM#RWD#RWE
.@GuthrieClinic is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: https://t.co/VFTePcAKCM
The #EAOnc Spring 2026 Group Meeting officially begins today! Looking forward to seeing you in Baltimore. Check in at the registration desk on the 4th floor before heading to your first session. 🩺🩻📈
How well does osimertinib—with or without chemotherapy—work to control EGFR-positive #LungCancer in patients not participating in a clinical trial? The PrE1702 #RealWorldData research study aims to find out. Learn more: https://t.co/OIWah87i9t #LCSM#RWD#RWE
.@uvahealthnews/@UVACancerCenter is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: https://t.co/VFTePcAKCM. cc: @ryangentzler
The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: https://t.co/OIWah87i9t #LCSM#RWD#RWE
.@RutgersCancer is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: https://t.co/VFTePcAKCM. cc: @DrHaigentz
.@FoxChaseCancer is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: https://t.co/VFTePcAKCM cc: @DesaiP_Oncdoc
.@teekayowo of @UMGCCC is leading PrE0510, a phase 2 #ClinicalTrial treating patients with extensive-stage small cell lung cancer (#SCLC) who have not yet had systemic therapy. Learn more: https://t.co/UUMDN1Nk2a #LCSM#LungCancer#SCLC
How well does osimertinib—with or without chemotherapy—work to control EGFR-positive #LungCancer in patients not participating in a clinical trial? The PrE1702 #RealWorldData research study aims to find out. Learn more: https://t.co/OIWah87i9t #LCSM#RWD#RWE